about
Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experiencePertussis Across the Globe: Recent Epidemiologic Trends From 2000-2013.Development of an LPS-based ELISA for diagnosis of Yersinia enterocolitica O:3 infections in Danish patients: a follow-up studyInvasive pneumococcal isolates from Danish infants (0 - 90 Days) during the years 1943 to 2013Pertussis serology: assessment of IgG anti-PT ELISA for replacement of the CHO cell assay.Seroprevalence of pertussis among Danish patients with cough of unknown etiology.Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012.Multilocus sequence types of invasive pneumococcal isolates from Danish infants (0-90 days) 2003-2013.Kinetics of the human antibody response against Salmonella enterica Serovars Enteritidis and Typhimurium determined by lipopolysaccharide enzyme-linked immunosorbent assayTemporal trends in Bordetella pertussis populations, Denmark, 1949-2010.Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009.Epidemiology of pertussis in Denmark, 1995 to 2013The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination.Global population structure and evolution of Bordetella pertussis and their relationship with vaccination.Detecting non-typhoid Salmonella in humans by ELISAs: a literature review.Detection of antibodies to Campylobacter in humans using enzyme-linked immunosorbent assays: a review of the literature.The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark.Seroepidemiology of pertussis in a cross-sectional study of an adult general population in Denmark.Rapid decay of Salmonella flagella antibodies during human gastroenteritis: a follow up study.Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.External Quality Assurance for Laboratory Identification and Capsular Typing of Streptococcus pneumoniaeProblem solved: a modified enzyme-linked immunosorbent assay for detection of human antibodies to pertussis toxin eliminates false-positive results occurring at analysis of heat-treated sera.The V410I (G1228A) variant of the caspase-10 gene is a common polymorphism of the Danish population.Evaluation of PCR methods for the diagnosis of pertussis by the European surveillance network for vaccine-preventable diseases (EUVAC.NET).A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vacSurveillance of Circulating Bordetella pertussis Strains in Europe during 1998 to 2015Laboratory diagnosis of pertussis: Agglutination is not suitableAntibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccineErratum to “Rapid decay of Salmonella flagella antibodies during human gastroenteritis: A follow up study” [J. Microbiol. Methods 62 (2005) 233–243]Pertactin-deficient isolates: evidence of increased circulation in Europe, 1998 to 2015Differences in the Impact of Pneumococcal Serotype Replacement in Individuals With and Without Underlying Medical ConditionsAntibody Specificity Following a Recent Bordetella pertussis Infection in Adolescence Is Correlated With the Pertussis Vaccine Received in ChildhoodDifferences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study
P50
Q26822908-15770666-94FD-446A-BFEC-0A73297BB002Q30488060-AA48DB2D-C640-4272-8424-075F027501A8Q33730521-DA29709A-BDEC-4BDF-BC53-8A70EC2AD6C0Q34090191-0E993456-1E92-4C7F-944D-DEB0DD5ABE92Q34414857-97163D5B-C96F-42D1-AF9E-677809D21126Q34431941-FBAB9341-B8B1-42E7-A64B-5C7C3CBDEB82Q35193398-5EF6D16D-09D1-4B7D-B04F-62B0481900E4Q35807525-D3268C61-3BEA-4BE7-AD6A-C86D21BC3BBEQ35946982-8F154DA4-5A04-4FFF-A5F1-AC6390537B87Q35979587-21C2734E-831A-4791-A739-5EC38E1CA0C0Q36558999-62E9B32E-BE29-4D03-8C25-C3F7AC779073Q37308086-C17E0D68-6B09-4737-A5FB-92C6C449552FQ37465209-4C0BB892-2A0E-46D3-BC5F-31EB36C444DBQ37714873-4F1CD448-29AD-42D5-B3EE-592E9DB5E8A0Q37950305-593A7A21-C678-43A3-9057-CA9236669D49Q38026318-45A1CE93-1E1A-422D-84AF-7A3505B43002Q38920259-974FE511-2091-4149-948E-0C5426A250D4Q39337495-9AB4AC5A-CDBF-43D9-99BD-3DF0C5ECF154Q41457731-E3D75FE7-7951-4B14-8653-EEFE6662EB59Q42200011-DC1B4369-E5EA-4680-A931-36A3522D3319Q42205779-37908864-5BA9-489A-A6D1-DC211FF00B96Q42378810-166D69A5-F6D4-4F68-8CA1-E4C0B3B1100EQ47614092-E52D4EC3-7184-4905-9AC0-2C221B96AE0AQ50566336-D1BB70B5-5310-4E87-BB09-3C032C7BC87BQ54262618-02BA6088-D83B-4BCD-917F-E4F89FACDFABQ56288717-E0B12115-E22C-48DF-AC2B-0C1C7B70AC7DQ57102695-0BA4AB76-F820-458F-92A9-0D5FF871F9B6Q57283942-08B2C3E4-6613-4C90-A1EC-F50EEDCDBBE0Q57283985-2E71F144-024F-4591-B902-7A552A88989DQ57284123-109D5420-3F58-47F1-91C6-4DBE58471C67Q63729077-9A2F2210-D127-4E0D-B83E-D980726903D2Q63729080-6C895292-A9D7-46F1-9F60-FD0E52529BD3Q91638960-17CBF869-0C15-4F13-887A-DA16DA987C6CQ95940522-2B4EF3C9-AE7F-44A5-98BA-17AE84B05B04
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
T Dalby
@ast
T Dalby
@nl
Tine Dalby
@en
Tine Dalby
@es
type
label
T Dalby
@ast
T Dalby
@nl
Tine Dalby
@en
Tine Dalby
@es
altLabel
T Dalby
@en
prefLabel
T Dalby
@ast
T Dalby
@nl
Tine Dalby
@en
Tine Dalby
@es
P106
P1153
8624022800
P21
P2798
P31
P496
0000-0003-4774-7091